Persistent Severe Acute Respiratory Syndrome Coronavirus 2 Pneumonia in Patients Treated with Anti-CD20 Monoclonal Antibodies

Nadav Furie, Michal Mandelboim, Neta Zuckerman, Ana Belkin, Lior Seluk, Inbal Shafran, Ronen Mass, Liran Levy, Sumit Chatterji, Erik Baltaxe, Michael Peled, Tiberiu Shulimzon, Abraham Avigdor, Sharon Amit, Amir Onn, Edith M. Marom, Galia Rahav*, Michael J. Segel*

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

Abstract

We report 8 cases of persistent severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pneumonia in patients previously treated with anti-CD20 monoclonal antibodies. Polymerase chain reaction of nasopharyngeal swabs for SARS-CoV-2 was negative in most cases; viral cell cultures confirmed that viable SARS-Co-2 virus was present. Four patients were treated with anti-SARS-CoV-2 hyperimmune globulins with rapid resolution of disease.

Original languageEnglish
Article numberofad464
JournalOpen Forum Infectious Diseases
Volume10
Issue number10
DOIs
StatePublished - 1 Oct 2023

Keywords

  • COVID19
  • SARS-CoV-2
  • antibody therapy
  • immune globulins
  • monoclonal antibody

Fingerprint

Dive into the research topics of 'Persistent Severe Acute Respiratory Syndrome Coronavirus 2 Pneumonia in Patients Treated with Anti-CD20 Monoclonal Antibodies'. Together they form a unique fingerprint.

Cite this